Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses

References

• Plotkin SA, Offit PA, eds. A short history of vaccination, 1-16 (Elsevier, New York, 2008).
   Google Scholar
• Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol 2010; 13:106 - 12; http://dx.doi.org/10.1016/j.mib.2009.12.001; PMID: 20079678
   PubMed Web of Science ®Google Scholar
• Sinha VR, Trehan A. Biodegradable microspheres for parenteral delivery. Crit Rev Ther Drug Carrier Syst 2005; 22:535 - 602; http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v22.i6.20; PMID: 16566705
   PubMed Web of Science ®Google Scholar
• Abbas AO, Donovan MD, Salem AK. Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. J Pharm Sci 2008; 97:2448 - 61; http://dx.doi.org/10.1002/jps.21215; PMID: 17918737
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm Res 2011; 28:215 - 36; http://dx.doi.org/10.1007/s11095-010-0241-4; PMID: 20721603
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009; 61:205 - 17; http://dx.doi.org/10.1016/j.addr.2008.12.013; PMID: 19272328
   PubMed Web of Science ®Google Scholar
• Zepp F. Principles of vaccine design-Lessons from nature. Vaccine 2010; 28:Suppl 3 C14 - 24; http://dx.doi.org/10.1016/j.vaccine.2010.07.020; PMID: 20713252
   PubMed Web of Science ®Google Scholar
• Ulery BD, Petersen LK, Phanse Y, Kong CS, Broderick SR, Kumar D, Ramer-Tait AE, Carrillo-Conde B, Rajan K, Wannemuehler MJ, et al. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci Rep 2011; 1:198; http://dx.doi.org/10.1038/srep00198; PMID: 22355713
   PubMed Web of Science ®Google Scholar
• Yoshida M, Babensee JE. Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J Biomed Mater Res A 2004; 71:45 - 54; http://dx.doi.org/10.1002/jbm.a.30131; PMID: 15368253
   PubMed Web of Science ®Google Scholar
• Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008; 26:5046 - 57; http://dx.doi.org/10.1016/j.vaccine.2008.07.035; PMID: 18680779
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother 2007; 30:469 - 78; http://dx.doi.org/10.1097/CJI.0b013e31802fd8c6; PMID: 17589287
   PubMed Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006; 40:1 - 9; http://dx.doi.org/10.1016/j.ymeth.2006.05.016; PMID: 16997708
   PubMed Web of Science ®Google Scholar
• Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808 - 12; http://dx.doi.org/10.1038/nature04596; PMID: 16489357
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488 - 96; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x; PMID: 15479434
   PubMed Web of Science ®Google Scholar
• Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011; 239:178 - 96; http://dx.doi.org/10.1111/j.1600-065X.2010.00978.x; PMID: 21198672
   PubMed Web of Science ®Google Scholar
• Geary SM, Lemke CD, Lubaroff DM, Salem AK. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother 2011; 60:1309 - 17; http://dx.doi.org/10.1007/s00262-011-1038-y; PMID: 21626029
   PubMed Web of Science ®Google Scholar
• Keijzer C, Slütter B, van der Zee R, Jiskoot W, van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One 2011; 6:e26684; http://dx.doi.org/10.1371/journal.pone.0026684; PMID: 22073184
   PubMed Web of Science ®Google Scholar
• Petersen LK, Ramer-Tait AE, Broderick SR, Kong CS, Ulery BD, Rajan K, Wannemuehler MJ, Narasimhan B. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 2011; 32:6815 - 22; http://dx.doi.org/10.1016/j.biomaterials.2011.05.063; PMID: 21703679
   PubMed Web of Science ®Google Scholar
• Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005; 57:391 - 410; http://dx.doi.org/10.1016/j.addr.2004.09.003; PMID: 15560948
   PubMed Web of Science ®Google Scholar
• Le Corre P, Rytting JH, Gajan V, Chevanne F, Le Verge R. In vitro controlled release kinetics of local anaesthetics from poly(D,L-lactide) and poly(lactide-co-glycolide) microspheres. J Microencapsul 1997; 14:243 - 55; http://dx.doi.org/10.3109/02652049709015336; PMID: 9132474
   PubMed Web of Science ®Google Scholar
• Greenwald D, Shumway S, Albear P, Gottlieb L. Mechanical comparison of 10 suture materials before and after in vivo incubation. J Surg Res 1994; 56:372 - 7; http://dx.doi.org/10.1006/jsre.1994.1058; PMID: 8152233
   PubMed Web of Science ®Google Scholar
• Blanco FC, Srinivasan P, Walk RM, Snyder JA, Behlke M, Salem AK, Vukmanovic S, Sandler AD. Development of an siRNA delivery system targeting macrophage function in-vivo. J Am Coll Surg 2012; 215:S74 - 74; http://dx.doi.org/10.1016/j.jamcollsurg.2012.06.204
   Google Scholar
• Hong L, Krishnamachari Y, Seabold D, Joshi V, Schneider G, Salem AK. Intracellular release of 17-β estradiol from cationic polyamidoamine dendrimer surface-modified poly (lactic-co-glycolic acid) microparticles improves osteogenic differentiation of human mesenchymal stromal cells. Tissue Eng Part C Methods 2011; 17:319 - 25; http://dx.doi.org/10.1089/ten.tec.2010.0388; PMID: 20883116
   PubMed Web of Science ®Google Scholar
• Hong L, Wei N, Joshi V, Yu Y, Kim N, Krishnamachari Y, Zhang Q, Salem AK. Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A 2012; 18:775 - 84; http://dx.doi.org/10.1089/ten.tea.2011.0432; PMID: 21988716
   PubMed Web of Science ®Google Scholar
• Intra J, Salem AK. Fabrication, characterization and in vitro evaluation of poly(D,L-lactide-co-glycolide) microparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery. J Pharm Sci 2010; 99:368 - 84; http://dx.doi.org/10.1002/jps.21840; PMID: 19670295
   PubMed Web of Science ®Google Scholar
• Intra J, Salem AK. Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells. J Drug Target 2011; 19:393 - 408; http://dx.doi.org/10.3109/1061186X.2010.504263; PMID: 20681752
   PubMed Web of Science ®Google Scholar
• Intra J, Zhang XQ, Williams RL, Zhu X, Sandler AD, Salem AK. Immunostimulatory sutures that treat local disease recurrence following primary tumor resection. Biomed Mater 2011; 6:011001; http://dx.doi.org/10.1088/1748-6041/6/1/011001; PMID: 21206000
   PubMedGoogle Scholar
• Santillan DA, Rai KK, Santillan MK, Krishnamachari Y, Salem AK, Hunter SK. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model. Am J Obstet Gynecol 2011; 205:e1 - 8; http://dx.doi.org/10.1016/j.ajog.2011.06.024; PMID: 21802065
   PubMedGoogle Scholar
• Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 2012; 7:e31472; http://dx.doi.org/10.1371/journal.pone.0031472; PMID: 22328935
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Intra J, Salem AK. Comparative study of poly (lactic-co-glycolic acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods. J Microencapsul 2008; 25:1 - 12; http://dx.doi.org/10.1080/02652040701659347; PMID: 18188727
   PubMed Web of Science ®Google Scholar
• Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Mark Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell RA, et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009; 27:3013 - 21; http://dx.doi.org/10.1016/j.vaccine.2009.03.034; PMID: 19428913
   PubMed Web of Science ®Google Scholar
• Raghuwanshi D, Mishra V, Suresh MR, Kaur K. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 2012; 30:7292 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.09.036; PMID: 23022399
   PubMed Web of Science ®Google Scholar
• Diesner SC, Wang XY, Jensen-Jarolim E, Untersmayr E, Gabor F. Use of lectin-functionalized particles for oral immunotherapy. Ther Deliv 2012; 3:277 - 90; http://dx.doi.org/10.4155/tde.11.146; PMID: 22834202
   PubMedGoogle Scholar
• Lassalle V, Ferreira ML. PLA nano- and microparticles for drug delivery: an overview of the methods of preparation. Macromol Biosci 2007; 7:767 - 83; http://dx.doi.org/10.1002/mabi.200700022; PMID: 17541922
   PubMed Web of Science ®Google Scholar
• Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J 2013; 15:85 - 94; http://dx.doi.org/10.1208/s12248-012-9418-6; PMID: 23054976
   PubMed Web of Science ®Google Scholar
• Zhang X-Q, Dahle CE, Weiner GJ, Salem AK. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci 2007; 96:3283 - 92; http://dx.doi.org/10.1002/jps.20978; PMID: 17497736
   PubMed Web of Science ®Google Scholar
• Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, Sandler AD. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother 2009; 58:517 - 30; http://dx.doi.org/10.1007/s00262-008-0574-6; PMID: 18719913
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18; http://dx.doi.org/10.1038/nm.2883; PMID: 22842478
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690; PMID: 20388795
   PubMed Web of Science ®Google Scholar
• Geary SM, Lemke CD, Lubaroff DM, Salem AK. The combination of a low-dose chemotherapeutic agent, 5-Fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One 2013; 8:e67904; http://dx.doi.org/10.1371/journal.pone.0067904; PMID: 23840786
   PubMed Web of Science ®Google Scholar
• Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14:1523 - 30; http://dx.doi.org/10.1016/S0264-410X(96)00099-0; PMID: 9014294
   PubMed Web of Science ®Google Scholar
• Reece JC, Vardaxis NJ, Marshall JA, Crowe SM, Cameron PU. Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes. Immunol Cell Biol 2001; 79:255 - 63; http://dx.doi.org/10.1046/j.1440-1711.2001.01011.x; PMID: 11380679
   PubMed Web of Science ®Google Scholar
• Gutierro I, Hernández RM, Igartua M, Gascón AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002; 21:67 - 77; http://dx.doi.org/10.1016/S0264-410X(02)00435-8; PMID: 12443664
   PubMed Web of Science ®Google Scholar
• Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007; 28:5344 - 57; http://dx.doi.org/10.1016/j.biomaterials.2007.08.015; PMID: 17825905
   PubMed Web of Science ®Google Scholar
• Katare YK, Muthukumaran T, Panda AK. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005; 301:149 - 60; http://dx.doi.org/10.1016/j.ijpharm.2005.05.028; PMID: 16023313
   PubMed Web of Science ®Google Scholar
• Igartua M, Hernández RM, Esquisabel A, Gascón AR, Calvo MB, Pedraz JL. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release 1998; 56:63 - 73; http://dx.doi.org/10.1016/S0168-3659(98)00077-7; PMID: 9801430
   PubMed Web of Science ®Google Scholar
• Lopac SK, Torres MP, Wilson-Welder JH, Wannemuehler MJ, Narasimhan B. Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres. J Biomed Mater Res B Appl Biomater 2009; 91:938 - 47; http://dx.doi.org/10.1002/jbm.b.31478; PMID: 19642209
   PubMed Web of Science ®Google Scholar
• Kumar N, Langer RS, Domb AJ. Polyanhydrides: an overview. Adv Drug Deliv Rev 2002; 54:889 - 910; http://dx.doi.org/10.1016/S0169-409X(02)00050-9; PMID: 12384314
   PubMed Web of Science ®Google Scholar
• Torres MP, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 2007; 28:108 - 16; http://dx.doi.org/10.1016/j.biomaterials.2006.08.047; PMID: 16965812
   PubMed Web of Science ®Google Scholar
• Carrillo-Conde B, Schiltz E, Yu J, Chris Minion F, Phillips GJ, Wannemuehler MJ, Narasimhan B. Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens. Acta Biomater 2010; 6:3110 - 9; http://dx.doi.org/10.1016/j.actbio.2010.01.040; PMID: 20123135
   PubMed Web of Science ®Google Scholar
• Göpferich A, Tessmar J. Polyanhydride degradation and erosion. Adv Drug Deliv Rev 2002; 54:911 - 31; http://dx.doi.org/10.1016/S0169-409X(02)00051-0; PMID: 12384315
   PubMed Web of Science ®Google Scholar
• Tamada JA, Langer R. Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci U S A 1993; 90:552 - 6; http://dx.doi.org/10.1073/pnas.90.2.552; PMID: 8421690
   PubMed Web of Science ®Google Scholar
• Determan AS, Wilson JH, Kipper MJ, Wannemuehler MJ, Narasimhan B. Protein stability in the presence of polymer degradation products: consequences for controlled release formulations. Biomaterials 2006; 27:3312 - 20; http://dx.doi.org/10.1016/j.biomaterials.2006.01.054; PMID: 16504288
   PubMed Web of Science ®Google Scholar
• Tamayo I, Irache JM, Mansilla C, Ochoa-Repáraz J, Lasarte JJ, Gamazo C. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin Vaccine Immunol 2010; 17:1356 - 62; http://dx.doi.org/10.1128/CVI.00164-10; PMID: 20631332
   PubMed Web of Science ®Google Scholar
• Mallapragada SK, Narasimhan B. Immunomodulatory biomaterials. Int J Pharm 2008; 364:265 - 71; http://dx.doi.org/10.1016/j.ijpharm.2008.06.030; PMID: 18662761
   PubMed Web of Science ®Google Scholar
• Huntimer L, Ramer-Tait AE, Petersen LK, Ross KA, Walz KA, Wang C, Hostetter J, Narasimhan B, Wannemuehler MJ. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery. Adv Healthc Mater 2013; 2:369 - 78; http://dx.doi.org/10.1002/adhm.201200181; PMID: 23184561
   PubMed Web of Science ®Google Scholar
• Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 2011; 6:e17642; http://dx.doi.org/10.1371/journal.pone.0017642; PMID: 21408610
   PubMed Web of Science ®Google Scholar
• Joshi VB, Geary SM, Carrillo-Conde BR, Narasimhan B, Salem AK. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles. Acta Biomater 2013; 9:5583 - 9; http://dx.doi.org/10.1016/j.actbio.2012.11.001; PMID: 23153760
   PubMed Web of Science ®Google Scholar
• Gould MP, Greene JA, Bhoj V, DeVecchio JL, Heinzel FP. Distinct modulatory effects of LPS and CpG on IL-18-dependent IFN-gamma synthesis. J Immunol 2004; 172:1754 - 62; PMID: 14734758
   PubMed Web of Science ®Google Scholar
• Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 2006; 60:655 - 8; http://dx.doi.org/10.1097/01.ta.0000199392.91772.44; PMID: 16531872
   PubMed Web of Science ®Google Scholar
• Saint-Lu N, Tourdot S, Razafindratsita A, Mascarell L, Berjont N, Chabre H, Louise A, Van Overtvelt L, Moingeon P. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009; 64:1003 - 13; http://dx.doi.org/10.1111/j.1398-9995.2009.01945.x; PMID: 19220212
   PubMed Web of Science ®Google Scholar
• Figueiredo L, Cadete A, Gonçalves LMD, Corvo ML, Almeida AJ. Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine 2012; 30:6551 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.08.050; PMID: 22947139
   PubMed Web of Science ®Google Scholar
• Li XY, Li X, Kong XY, Shi S, Guo G, Zhang J, Luo F, Zhao X, Wei YQ, Qian ZY, et al. Preparation of N-trimethyl chitosan-protein nanoparticles intended for vaccine delivery. J Nanosci Nanotechnol 2010; 10:4850 - 8; http://dx.doi.org/10.1166/jnn.2010.2211; PMID: 21125819
   PubMed Web of Science ®Google Scholar
• Fan W, Yan W, Xu ZS, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces 2012; 90:21 - 7; http://dx.doi.org/10.1016/j.colsurfb.2011.09.042; PMID: 22014934
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004; 100:5 - 28; http://dx.doi.org/10.1016/j.jconrel.2004.08.010; PMID: 15491807
   PubMed Web of Science ®Google Scholar
• Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2013; 34:1270 - 80; http://dx.doi.org/10.1016/j.biomaterials.2012.10.013; PMID: 23140978
   PubMed Web of Science ®Google Scholar
• Oliveira CR, Rezende CM, Silva MR, Pêgo AP, Borges O, Goes AM. A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis. PLoS Negl Trop Dis 2012; 6:e1894; http://dx.doi.org/10.1371/journal.pntd.0001894; PMID: 23209848
   PubMedGoogle Scholar
• Malik B, Goyal AK, Zakir F, Vyas SP. Surface engineered nanoparticles for oral immunization. J Biomed Nanotechnol 2011; 7:132 - 4; http://dx.doi.org/10.1166/jbn.2011.1236; PMID: 21485838
   PubMed Web of Science ®Google Scholar
• Mangal S, Pawar D, Agrawal U, Jain AK, Vyas SP. Evaluation of mucoadhesive carrier adjuvant: Toward an oral anthrax vaccine. Artif Cells Nanomed Biotechnol 2013; Forthcoming http://dx.doi.org/10.3109/21691401.2013.769447; PMID: 23452384
   PubMedGoogle Scholar
• Koppolu B, Zaharoff DA. The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials 2013; 34:2359 - 69; http://dx.doi.org/10.1016/j.biomaterials.2012.11.066; PMID: 23274070
   PubMed Web of Science ®Google Scholar
• Jiang L, Qian F, He X, Wang F, Ren D, He Y, Li K, Sun S, Yin C. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. J Gene Med 2007; 9:253 - 64; http://dx.doi.org/10.1002/jgm.1017; PMID: 17397104
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv 2012; 9:1051 - 67; http://dx.doi.org/10.1517/17425247.2012.697455; PMID: 22708875
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178 - 87; http://dx.doi.org/10.1056/NEJMoa1101245; PMID: 22150036
   PubMed Web of Science ®Google Scholar
• Gogev S, de Fays K, Versali MF, Gautier S, Thiry E. Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1. Vaccine 2004; 22:1946 - 53; http://dx.doi.org/10.1016/j.vaccine.2003.11.011; PMID: 15121307
   PubMed Web of Science ®Google Scholar
• Gogev S, Vanderheijden N, Lemaire M, Schynts F, D’Offay J, Deprez I, Adam M, Eloit M, Thiry E. Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD. Vaccine 2002; 20:1451 - 65; http://dx.doi.org/10.1016/S0264-410X(01)00458-3; PMID: 11818166
   PubMed Web of Science ®Google Scholar
• Hagenaars N, Mastrobattista E, Verheul RJ, Mooren I, Glansbeek HL, Heldens JG, van den Bosch H, Jiskoot W. Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharm Res 2009; 26:1353 - 64; http://dx.doi.org/10.1007/s11095-009-9845-y; PMID: 19224344
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, Borisova O, Ahmatova N, Kurbatova E, Mazurina S, et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol 2009; 81:494 - 506; http://dx.doi.org/10.1002/jmv.21415; PMID: 19152418
   PubMed Web of Science ®Google Scholar
• Lemke CD, Graham JB, Geary SM, Zamba G, Lubaroff DM, Salem AK. Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. Mol Pharm 2011; 8:1652 - 61; http://dx.doi.org/10.1021/mp100464y; PMID: 21780831
   PubMed Web of Science ®Google Scholar